The principle of the modified one-stage FVIII assay for emicizumab measurement relies upon measuring the degree of correction of the APTT when patient plasma is added to FVIII deficient plasma. The degree of correction is related to the amount of emicizumab in the patient’s sample. Quantification of the degree of correction is enabled by using a calibration curve constructed using the Emicizumab Calibrator.